Crossmark

Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget’s disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget’s disease patients

Crossref DOI link: https://doi.org/10.1007/s00262-024-03846-8

Published Online: 2024-10-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Jiawen

Chen, Yurong

Zhang, Xiuyuan

Tong, Ziyan

Weng, Shanshan

Zhu, Ning

Yuan, Ying
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82373415)

Zhejiang Provincial Clinical Research Center for CANCER (2022E50008)

Provincial Key R&D Program of Zhejiang Province (2021C03125)
License Information

Text and Data Mining valid from 2024-10-03

Version of Record valid from 2024-10-03
More Information

Article History

Received: 7 August 2024

Accepted: 23 September 2024

First Online: 3 October 2024

Declarations

:

: The authors declare no competing interests.

: No ethical approval is required.

Document is current

Any future updates will be listed below